These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12040451)

  • 21. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.
    Hirano T; Ishihara K; Hibi M
    Oncogene; 2000 May; 19(21):2548-56. PubMed ID: 10851053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3.
    Tsuyama N; Danjoh I; Otsuyama K; Obata M; Tahara H; Ohta T; Ishikawa H
    Biochem Biophys Res Commun; 2005 Nov; 337(1):201-8. PubMed ID: 16188230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis.
    Plowright EE; Li Z; Bergsagel PL; Chesi M; Barber DL; Branch DR; Hawley RG; Stewart AK
    Blood; 2000 Feb; 95(3):992-8. PubMed ID: 10648414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.
    Catlett-Falcone R; Landowski TH; Oshiro MM; Turkson J; Levitzki A; Savino R; Ciliberto G; Moscinski L; Fernández-Luna JL; Nuñez G; Dalton WS; Jove R
    Immunity; 1999 Jan; 10(1):105-15. PubMed ID: 10023775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.
    Brocke-Heidrich K; Kretzschmar AK; Pfeifer G; Henze C; Löffler D; Koczan D; Thiesen HJ; Burger R; Gramatzki M; Horn F
    Blood; 2004 Jan; 103(1):242-51. PubMed ID: 12969979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Capillarisin inhibits constitutive and inducible STAT3 activation through induction of SHP-1 and SHP-2 tyrosine phosphatases.
    Lee JH; Chiang SY; Nam D; Chung WS; Lee J; Na YS; Sethi G; Ahn KS
    Cancer Lett; 2014 Apr; 345(1):140-8. PubMed ID: 24333736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.
    Usui E; Nishii K; Katayama N; Lorenzo V F; Chen F; Monma F; Otsuki T; Shiku H
    Hematol J; 2004; 5(6):505-12. PubMed ID: 15570293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells?
    Kovacs E
    Leuk Res; 2010 Jul; 34(7):912-6. PubMed ID: 19762082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines.
    Jernberg H; Pettersson M; Kishimoto T; Nilsson K
    Leukemia; 1991 Mar; 5(3):255-65. PubMed ID: 1707469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.
    Chatterjee M; Hönemann D; Lentzsch S; Bommert K; Sers C; Herrmann P; Mathas S; Dörken B; Bargou RC
    Blood; 2002 Nov; 100(9):3311-8. PubMed ID: 12384432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
    Burger R; Bakker F; Guenther A; Baum W; Schmidt-Arras D; Hideshima T; Tai YT; Shringarpure R; Catley L; Senaldi G; Gramatzki M; Anderson KC
    Br J Haematol; 2003 Dec; 123(5):869-78. PubMed ID: 14632778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice.
    Takeda K; Kaisho T; Yoshida N; Takeda J; Kishimoto T; Akira S
    J Immunol; 1998 Nov; 161(9):4652-60. PubMed ID: 9794394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited.
    Friederichs K; Schmitz J; Weissenbach M; Heinrich PC; Schaper F
    Eur J Biochem; 2001 Dec; 268(24):6401-7. PubMed ID: 11737194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
    Alas S; Bonavida B
    Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study on the biological activity and molecular mechanism of IFNalpha on human myeloma cell line Sko-007].
    Song L; Li Y; Sun Y; Shen B
    Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):517-9. PubMed ID: 12482347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells.
    Nagel-Wolfrum K; Buerger C; Wittig I; Butz K; Hoppe-Seyler F; Groner B
    Mol Cancer Res; 2004 Mar; 2(3):170-82. PubMed ID: 15037656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
    Slørdahl TS; Abdollahi P; Vandsemb EN; Rampa C; Misund K; Baranowska KA; Westhrin M; Waage A; Rø TB; Børset M
    Oncotarget; 2016 May; 7(19):27295-306. PubMed ID: 27036022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.
    Ferlin M; Noraz N; Hertogh C; Brochier J; Taylor N; Klein B
    Br J Haematol; 2000 Nov; 111(2):626-34. PubMed ID: 11122111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells.
    Liu S; Ma Z; Cai H; Li Q; Rong W; Kawano M
    Eur J Haematol; 2010 Feb; 84(2):137-44. PubMed ID: 19878271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.